Skip to main content
Figure 4 | BMC Endocrine Disorders

Figure 4

From: The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

Figure 4

Effects of fenofibrate and pioglitazone on osteoblast differentiation. Rat primary bone marrow cells were treated with increasing doses of PPAR agonists for 21 days and stained sequentially for ALP (A), calcium (B) and collagen (C). a = p < 0.05 compared with vehicle treated cells.

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us